alexa Open Access Pharmacovigilance Databases: Analysis Of 11 Databases
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

8th Global Pharmacovigilance & Drug Safety Summit

Delphine Bertram
Xendo B.V., Netherlands
ScientificTracks Abstracts: J Clin Trial
DOI: 10.4172/2167-0870-C1-016
The concept of transparency regarding scientific data is more and more obvious, this work aims at describing and analyzing what kind of safety data can be obtained from Pharmacovigilance (PV) databases that offer public access. Nine national pharmacovigilance databases (Australia, Canada, Denmark, Germany, Netherlands, New-Zealand, Japan, United Kingdom, USA) plus the World Health Organization (Vigibase) and the European Pharmacovigilance databases were compared according to the type of data provided, the possible requests (by drug, by adverse reaction) and the format of the safety data. Public access to PV databases is thus classified as high, medium or low. The results show that six databases grant case-level access, the others only provide aggregated data. In terms of general case information, the USA and Canada come first by sharing case ID, the type of report, the reporter and their qualification, whereas Vigibase does not provide any general information. Other databases mostly provide only one of these three items: Source, case ID, or type of report. Overall, the databases from Denmark, Japan, Netherlands, UK and VigiBase were classified as providing a low level of access to available safety information; those from Australia, Eudra Vigilance, Germany and New Zealand as providing a medium level of access; and those from the USA and Canada, as providing a high level of access. The 11 PV databases were analyzed, except for those in North America, provide limited information. This may be acceptable for patient use but not for research purposes.

Delphine Bertram, PharmD, PhD, has more than 12 years of experience in managing the safety of clinical trials. She has built and managed the Vigilance Unit of the Second Public French Hospital. She has hosted and managed European and French Health Authorities inspections (preparation, conduct and CAPA management), planned and executed internal/external audits. She has extensive knowledge in the international regulatory (ICH, FDA guidance’s, GVP, MEDDEV) environment, for both pre- and post-marketing products, e-Health and social media monitoring. She has co-developed a free application to allow patients and healthcare professionals to report drug adverse effects to the health authority. She has a particular interest in e-Health precisely in the use of social data to improve drug surveillance.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version